Leia a Última Edição!

II Serie Volume 31 Number 02
February 2018


menu esquerda

  1- Factors of recurrence of intraepithelial lesions of the uterine cervix.

2- Duodenoscopy and endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of biliary and pancreatic pathology.

3- Mephedrone (?Meow Meow?), The New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynimics and Clinical and Forensic Issues

4- Natural history of fetal pyelocaliectasia.

5- Erysipelas.

6- Antidepressant drugs.

7- Pressure ulcer management--Evidence-based interventions.

8- Traumatic Brain Injury: Integrated Approach

9- Genital ulcers caused by sexually transmitted diseases: current therapies, diagnosis and their relevance in HIV pandemy.

10- Current management of gout.

11- Livedo vasculitis.

12- Tarlov's cyst: definition, etiopathogenesis, propaedeutic and treatment.

13- Antibiotic treatment of uncomplicated cystitis in non-pregnant women up to menopause.

14- Uterine inversion.

15- Urolithiasis and renal colic. Therapeutic approach in urology.

16- Surgical basic skills: surgical sutures.

17- Rhabdomyolysis.

18- Glioblastoma multiforme... with multifocal presentation.

19- Intrahepatic cholestasis in pregnancy. Its etiopathogenesis, prognosis and therapy.

20- Differences between SSRI's pharmacokinetics and pharmacodinamics.


Physician Involvement in the Activities of the European Medicines Agency

For more than two decades of activity, the European Medicines Agency has been operating as part of a network with the national medicines agencies in Europe, bringing together - in its various scientific committees and working groups - European experts on a wide range of topics related to quality assurance, safety and efficacy of medicines. The work carried out within the European Medicines Agency activities and the conclusions reached at European level affect millions of citizens. The European Medicines Agency considers that it is of great importance to maintain, in a sustainable and consistent manner, the active participation of general practitioners, as well as other medical specialists, in the process of medicines’ evaluation and supervision. This article summarizes how the participation of doctors and health professionals in general is promoted in the European Medicines Agency activities.
Keywords: Drug Approval; European Union; Government Agencies; Health Personnel

Full article available here. (Portuguese only)